Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2010 2
2011 3
2012 1
2014 3
2015 3
2016 5
2017 3
2018 3
2019 2
2020 3
2021 7
2022 6
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Detection of Cancer Stem Cells in Normal and Dysplastic/Leukemic Human Blood.
De Stefano A, Cappellini A, Casalin I, Paolini S, Parisi S, Marvi MV, Fazio A, Neri I, Koufi FD, Ratti S, Finelli C, Curti A, Manzoli L, Cocco L, Follo MY. De Stefano A, et al. Among authors: parisi s. Methods Mol Biol. 2024;2777:163-176. doi: 10.1007/978-1-0716-3730-2_12. Methods Mol Biol. 2024. PMID: 38478343
Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression.
Casalin I, De Stefano A, Ceneri E, Cappellini A, Finelli C, Curti A, Paolini S, Parisi S, Zannoni L, Boultwood J, McCubrey JA, Suh PG, Ramazzotti G, Fiume R, Ratti S, Manzoli L, Cocco L, Follo MY. Casalin I, et al. Among authors: parisi s. Adv Biol Regul. 2024 Jan;91:101014. doi: 10.1016/j.jbior.2024.101014. Epub 2024 Jan 12. Adv Biol Regul. 2024. PMID: 38242820 Free article.
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study.
Marconi G, Candoni A, Di Nicola R, Sartor C, Parisi S, Abbenante M, Nanni J, Cristiano G, Zannoni L, Lazzarotto D, Giannini B, Baldazzi C, Bandini L, Ottaviani E, Testoni N, Bezzi CDG, Abd-Alatif R, Ciotti G, Fanin R, Martinelli G, Paolini S, Ricci P, Cavo M, Papayannidis C, Curti A. Marconi G, et al. Among authors: parisi s. Cancer Med. 2023 May;12(10):11838-11848. doi: 10.1002/cam4.5858. Epub 2023 Mar 31. Cancer Med. 2023. PMID: 36999931 Free PMC article.
Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.
Meazza R, Ruggeri L, Guolo F, Minetto P, Canevali P, Loiacono F, Ciardelli S, Bo A, Luchetti S, Serio A, Zannoni L, Retière C, Colomar-Carando N, Parisi S, Curti A, Lemoli RM, Pende D. Meazza R, et al. Among authors: parisi s. Front Immunol. 2023 Feb 14;14:1111419. doi: 10.3389/fimmu.2023.1111419. eCollection 2023. Front Immunol. 2023. PMID: 36865545 Free PMC article.
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
Mongiorgi S, De Stefano A, Ratti S, Indio V, Astolfi A, Casalin I, Pellagatti A, Paolini S, Parisi S, Cavo M, Pession A, McCubrey JA, Suh PG, Manzoli L, Boultwood J, Finelli C, Cocco L, Follo MY. Mongiorgi S, et al. Among authors: parisi s. Clin Epigenetics. 2023 Feb 20;15(1):27. doi: 10.1186/s13148-023-01441-9. Clin Epigenetics. 2023. PMID: 36803590 Free PMC article.
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment.
Sartor C, Arpinati M, Chirumbolo G, Dozza L, Cristiano G, Nanni J, Marconi G, Robustelli V, Vigliotta I, Parisi S, Terragna C, Testoni N, Paolini S, Martinelli G, Curti A, Cavo M, Papayannidis C. Sartor C, et al. Among authors: parisi s. Hematol Oncol. 2022 Oct;40(4):734-742. doi: 10.1002/hon.3029. Epub 2022 Jun 5. Hematol Oncol. 2022. PMID: 35618655
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
Parisi S, Ruggeri L, Dan E, Rizzi S, Sinigaglia B, Ocadlikova D, Bontadini A, Giudice V, Urbani E, Ciardelli S, Sartor C, Cristiano G, Nanni J, Zannoni L, Chirumbolo G, Arpinati M, Lewis RE, Bonifazi F, Marconi G, Martinelli G, Papayannidis C, Paolini S, Velardi A, Cavo M, Lemoli RM, Curti A. Parisi S, et al. Front Immunol. 2022 Jan 31;12:804988. doi: 10.3389/fimmu.2021.804988. eCollection 2021. Front Immunol. 2022. PMID: 35173709 Free PMC article.
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents.
Papayannidis C, Nanni J, Cristiano G, Marconi G, Sartor C, Parisi S, Zannoni L, Saed R, Ottaviani E, Bandini L, Testoni N, Baldazzi C, Solli V, Ricci P, Di Giovanni Bezzi C, Abd-Alatif R, Stanzani M, Paolini S, Cavo M, Curti A. Papayannidis C, et al. Among authors: parisi s. Eur J Haematol. 2022 Jun;108(6):449-459. doi: 10.1111/ejh.13753. Epub 2022 Feb 28. Eur J Haematol. 2022. PMID: 35156731 Free PMC article.
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia.
Ravaioli F, Marconi G, Martinelli G, Dajti E, Sartor C, Abbenante MC, Alemanni LV, Nanni J, Rossini B, Parisi S, Colecchia L, Cristiano G, Marasco G, Vestito A, Paolini S, Bonifazi F, Curti A, Festi D, Cavo M, Colecchia A, Papayannidis C. Ravaioli F, et al. Among authors: parisi s. Cancer Med. 2022 Feb;11(3):618-629. doi: 10.1002/cam4.4390. Epub 2021 Dec 30. Cancer Med. 2022. PMID: 34970853 Free PMC article.
43 results